Nifedipine and propranolol: a beneficial drug interaction

The American Journal of Medicine
H J DargieS Krikler

Abstract

The antianginal effects of two active drugs, nifedipine and propranolol, alone in combination, were compared with those of placebo in a double-blind clinical trial that included 16 patients with chronic stable angina triggered by exertion. A low dose and a high dose of the active drugs were used (nifedipine, 30 and 60 mg/day; propranolol, 240 and 280 mg/day). Precordial exercise mapping and continuous electrocardiographic recordings were used to assess objective response to therapy, and the patients were asked to keep a diary of episodes of chest pain and consumption of nitroglycerin tablets for subjective appraisal. Both frequency of chest pain and nitroglycerin consumption were significantly reduced by each of the active drugs when compared with placebo, and the combination of nifedipine and propranolol added significantly to the effectiveness. Reductions in area of ischemia and number of episodes of ST segment depression on 48-hour ambulatory electrocardiographic monitoring corroborated the efficacy of each active treatment with respect to placebo. Nearly 60 percent of all episodes of ST segment depression were painless and responded to the active treatment in the same manner as did the episodes associated with chest pain. S...Continue Reading

References

Dec 1, 1978·British Heart Journal·K M FoxJ P Shillingford
Jun 5, 1980·The New England Journal of Medicine·E AntmanE Braunwald
Sep 1, 1958·Circulation Research·L N KATZ, H FEINBERG

❮ Previous
Next ❯

Citations

May 1, 1988·Cardiovascular Drugs and Therapy·P R Lichtlen
Jan 1, 1991·European Journal of Clinical Pharmacology·S H Thomas
Jan 1, 1985·European Journal of Clinical Pharmacology·M R WilkinsS J Laugher
Jan 1, 1983·European Journal of Clinical Pharmacology·S Dean, M J Kendall
Jan 1, 1986·European Journal of Clinical Pharmacology·J LoboM J Kendall
Aug 1, 1990·Cardiovascular Drugs and Therapy·R W Nesto
Sep 1, 1986·Canadian Anaesthetists' Society Journal·P N FymanP A Casthely
Jan 29, 1988·The American Journal of Cardiology·C J PepineN Norvell
Jan 1, 1989·Zeitschrift für Kardiologie·H Roskamm, C Droste
Nov 8, 1988·European Journal of Pharmacology·D J DunckerP D Verdouw
Jan 1, 1983·Pharmacology & Therapeutics·W G Nayler, J D Horowitz
Jan 1, 1990·Pharmacology & Therapeutics·W KirchG G Belz
Apr 1, 1984·Journal of the American College of Cardiology·M TolinsG L Pierpont
Feb 1, 1985·Journal of the American College of Cardiology·R L FeldmanC J Pepine
Dec 23, 1982·The New England Journal of Medicine·E Braunwald
Sep 1, 1991·British Journal of Clinical Pharmacology·H L ElliottJ L Reid
Jan 1, 1985·Reviews on Drug Metabolism and Drug Interactions·R L Klieman, S H Stephenson
Nov 1, 1983·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W M BennettI Singer
Aug 1, 1985·Mayo Clinic Proceedings·C ShubM D McGoon
Feb 1, 1990·Mayo Clinic Proceedings·C Shub
Feb 1, 1984·The American Journal of Medicine·D Hoekenga, J Abrams
May 1, 1985·The American Journal of Cardiology·K TordjmanM Bursztyn
Mar 15, 1985·The American Journal of Cardiology·W H FrishmanD D Michie
Jan 25, 1985·The American Journal of Cardiology·R G McAllisterR A Blouin
Jan 25, 1985·The American Journal of Cardiology·M B LeonS E Epstein
May 1, 1992·Progress in Cardiovascular Diseases·D Mulcahy, K Fox
Jan 1, 1982·International Journal of Cardiology·R A O'Rourke
Jan 1, 1988·American Heart Journal·P F Cohn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.